Alkermes' LUMRYZ Phase 3 Study for Idiopathic Hypersomnia Meets All Endpoints
ALKS sits 42% above its 52-week low of $25.165.
Summary
Alkermes announced positive topline results from its Phase 3 REVITALYZ study, showing LUMRYZ significantly improved excessive daytime sleepiness and disease severity in adults with idiopathic hypersomnia. The company plans to file an sNDA by year-end 2026, though marketing for this indication is restricted until March 2028.
Key Events · Product Development and Regulatory · ALKS
-
Positive Phase 3 Results
LUMRYZ met all primary and key secondary endpoints in the REVITALYZ study for idiopathic hypersomnia, demonstrating statistically significant improvements in excessive daytime sleepiness and disease severity.
-
Consistent Safety Profile
The safety profile of LUMRYZ in the study was consistent with previously observed data, with no new safety signals identified.
-
Planned sNDA Submission
Alkermes intends to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026 for this new indication.
-
Marketing Restriction
Commercialization of LUMRYZ for idiopathic hypersomnia is restricted until March 1, 2028, even if FDA approval is received earlier, due to a previously disclosed settlement.
Analysis · ALKS · Life Sciences
This filing reports successful Phase 3 clinical trial results for LUMRYZ in idiopathic hypersomnia, a rare sleep disorder with limited treatment options. Meeting all primary and key secondary endpoints with a consistent safety profile is a significant positive for Alkermes, expanding the potential market for an already approved drug. While an sNDA filing is planned for late 2026, commercialization for this new indication is restricted until March 2028 due to a prior settlement, delaying potential revenue generation.
At the time of this filing, ALKS was trading at $35.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $25.17 to $36.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.